Mission Statement, Vision, & Core Values (2026) of Roche Holding AG.

Discover how Roche Holding AG - founded more than 125 years ago and now employing over 100,000 people worldwide - combines diagnostics and pharmaceuticals to 'do now what patients need next,' translating a mission of urgent patient impact into tangible outcomes like launching 21 new medicines in 2024 across oncology, neurology and haematology; driven by a vision to give people 'more time with the people they love' while reducing costs for patients and health systems, and anchored in core values of Integrity, Courage and Passion, Roche pairs ambitious sustainability targets - including net-zero by 2050 and sourcing over 50% of its energy from renewables - with an integrated R&D approach that aims to prevent, stop or cure diseases with the highest societal burden.

Roche Holding AG (0QQ6.L) - Intro

• Global footprint spanning more than 100 countries with a workforce exceeding 100,000 employees (circa 105,000).
• Integrated diagnostics + pharma strategy to accelerate development, improve outcomes and optimize care pathways.
• Strong R&D orientation - sustained high investment to drive pipeline and lifecycle management.

• Sustainability targets: net‑zero greenhouse gas emissions by 2050 and sourcing over 50% of energy from renewable sources.
• Diversity & inclusion focus to foster equitable career development and an inclusive culture across global sites.

• Mission - to deliver innovative medicines and diagnostics that improve lives globally by advancing personalised healthcare and bridging prevention, diagnosis and treatment.
• Vision - to be the partner of choice for precision health, combining novel therapies and cutting‑edge diagnostics to reduce the societal burden of serious diseases.
• Core values - science‑driven innovation, patient focus, integrity, courage to take long‑term bets, collaboration across functions and respect for people.

• Pipeline acceleration and life‑cycle management in oncology, immunology, neuroscience and haematology.
• Leveraging diagnostics data and digital solutions to enable earlier detection, better patient stratification and optimized treatment decisions.
• Maintain financial strength to fund discovery, external innovation and manufacturing scale while delivering returns to shareholders.

• 2024 launches: 21 new medicines introduced or approved, expanding standards of care across core therapeutic areas.
• High R&D intensity: sustained double‑digit percentage of sales reinvested into research and development.
• Global manufacturing and diagnostics capacity enabling broad access to test‑and‑treat solutions across markets.

Roche Holding AG (0QQ6.L) - Overview

Mission Statement - 'Do now what patients need next.' This encapsulates Roche Holding AG's urgent, patient-centric mandate to deliver effective therapies and diagnostics today while advancing innovations for tomorrow. The mission drives prioritization of treatments with immediate clinical impact, shortens time-to-patient for new solutions, and aligns R&D and commercial strategies to meet pressing unmet needs.

Vision - To be the world's leader in personalized healthcare by combining pharmaceuticals and diagnostics to deliver targeted, effective care that improves outcomes and optimizes healthcare systems globally.

• Personalized healthcare: integrating diagnostics and therapeutics to match the right treatment to the right patient.
• Rapid impact: prioritizing programs that provide measurable patient benefit in the near term.
• Sustainable innovation: investing in platform technologies (e.g., genomics, companion diagnostics, digital health) to build long-term pipelines.

Core Values - Roche's culture and decision-making are shaped by a set of guiding principles that support the mission and vision.

• Patient-centricity - decisions and priorities driven by patient needs and outcomes.
• Science-driven excellence - rigorous investment in R&D and evidence generation.
• Integrity and compliance - ethical conduct, data transparency, and regulatory adherence.
• Collaboration - cross-functional and external partnerships to accelerate development and access.
• Long-term responsibility - sustainable operations, access initiatives, and reinvestment in innovation.

How the mission translates into measurable action:

• Pipeline prioritization: accelerated programs for high-unmet-need oncology and rare-disease indications with expedited regulatory pathways.
• Diagnostics integration: companion diagnostics deployed alongside targeted therapies to reduce time to correct treatment.
• Investment focus: sustaining ~20%+ of sales in R&D to maintain rapid innovation cadence and near-term patient impact.
• Access strategies: pricing, partnerships, and patient support programs to ensure timely availability in varied markets.

Examples of mission-aligned outcomes (recent years):

• Launches of targeted oncology agents accompanied by validated companion diagnostics, shortening diagnosis-to-treatment intervals.
• Expansion of molecular diagnostics capacity to support pandemic response and routine clinical testing.
• Strategic collaborations with biotech and academic centers to accelerate translational programs from discovery to clinic.

Stakeholder metrics tied to the mission and values:

Further investor and profile information can be found here: Exploring Roche Holding AG Investor Profile: Who's Buying and Why?

Roche Holding AG (0QQ6.L) - Mission Statement

• Extend and improve patients' lives through precision medicines and advanced diagnostics.
• Reduce total cost of care by enabling earlier detection, targeted treatment, and better disease management.
• Scale access and affordability to make solutions sustainable for healthcare systems worldwide.
• Integrate diagnostics and pharmaceuticals to create value across the patient pathway.

• Patient focus: decisions anchored in measurable patient outcomes and quality of life.
• Science-led innovation: prioritizing breakthrough research, biomarkers, and personalized care.
• Collaboration: partnerships with academia, health systems, and industry to accelerate translation.
• Integrity and compliance: ethical conduct, data transparency, and regulatory adherence.
• Sustainability: reducing environmental footprint and improving healthcare affordability.

• Pipeline prioritization: focus on diseases with high unmet need and potential to extend meaningful life-years.
• Diagnostics integration: investing in companion diagnostics and real-world data to target therapies and lower downstream costs.
• Value-based approaches: pilots and partnerships to align payment with outcomes and cost-effectiveness.
• Global access programs: tiered pricing, partnerships, and capacity-building to broaden reach.

Roche Holding AG (0QQ6.L) - Vision Statement

• Integrity - openness, honesty, ethical conduct, and transparency in research, commercial operations, and stakeholder engagement.
• Courage - entrepreneurial risk-taking, rigorous experimentation, and willingness to push scientific and business boundaries to catalyze breakthroughs.
• Passion - commitment to energize, engage, and inspire colleagues, partners, and the wider healthcare community to improve patient lives.

• How values translate into action:
  • Integrity: transparent clinical trial reporting, compliance programs, and ethical supply-chain practices.
  • Courage: advancing high-risk, high-reward oncology and neuroscience programs; pursuing platform technologies.
  • Passion: employee engagement initiatives, patient-centric programs, and advocacy for diagnostic-driven care.

• Pipeline robustness: number of oncology and immunology assets in Phase II/III and regulatory submissions (dozens of late-stage assets across indications).
• Diagnostic reach: deployment of molecular and digital pathology platforms across tens of thousands of laboratories and health systems globally.
• Access & partnerships: collaborative agreements with health systems, biotech partners, and non-profit organizations to expand access and real-world evidence generation.